Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body Composition Sub-study of D2EFT
NCT03675815Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Dec 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by The Kirby Institute. Primary endpoints: Waist-to-hip ratio at 48 weeks and Total-to-HDL cholesterol ratio at 48 weeks. Started Dec 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03675815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675815.